FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!

In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.

For patients with chronic lymphocytic leukemia, molecular analysis can provide critical information. Dr. John C. Byrd discusses the importance of IGHV and TP53 sequencing and the clinical value they provide.

As the field of chronic lymphocytic leukemia continues to evolve, what we can look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Lindsey Roeker shares what she expects to see at this year’s ASH meeting.

For patients with advanced non-small cell lung cancer, broad molecular testing can be both a solution and a challenge. Here to share key challenges for next-generation sequencing is Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center in California.

Has the COVID-19 pandemic limited our treatment options for patients with mantle cell lymphoma? To answer this, Dr. Thomas Kipps reviews key treatment challenges and considerations for these patients amid the ongoing pandemic.

When determining a patient’s therapy regimen, what disease-related factors do we need to keep in mind? Dr. Nicole Lamanna, a Hematologist/Oncologist at Columbia University Medical Center, share strategies for tailoring chronic lymphocytic leukemia treatment and how that can impact patient outcomes.

What do the NCCN guidelines recommend for the management of patients with chronic lymphocytic leukemia, or CLL, and mantle cell lymphoma, or MCL? Dr. Charles Turck is joined by Dr. Thomas Kipps to talk about prognostic risk indicators, current therapeutic agents, and adverse events for patients with CLL and MCL.

While the management and treatment of HER2-mutated non-small cell lung cancer continues to evolve, patients still face many unmet needs. Dr. Nicolas Girard, a pneumologist and Professor of Respiratory Medicine at Versailles Saint Quentin University, explores these unmet needs and how we can solve them.

Couldn’t attend the 2021 European Society of Medical Oncology (ESMO) Conference? No worries—ReachMD host Dr. Nabil Saba is here to share the latest updates in head and neck cancer from the 2021 ESMO Conference.